The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2023 | Myeloma highlights from SOHO 2023: updates with the use of novel targeted immunotherapies
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares the most exciting discussions in the field of multiple myeloma from SOHO 2023, drawing focus on updates with the use of novel targeted immunotherapies. Prof. Martin discusses the success of ciltacabtagene autoleucel (cilta-cel) in heavily pre-treated patients, the real-world application of teclistamab, and toxicities associated with the use of novel immunotherapies. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: BMS, Janssen, Sanofi Consultant: Pfizer, GSK
